ARENA PHARMACEUTICALS INC Form 8-K October 17, 2005

# **UNITED STATES**

# **SECURITIES AND EXCHANGE COMMISSION**

WASHINGTON, D.C. 20549

# FORM 8-K

## **Current Report**

#### Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): October 17, 2005

# Arena Pharmaceuticals, Inc.

(Exact Name of Registrant as Specified in Charter)

Delaware 000-31161 23-2908305

23-2908305

(State or Other Jurisdiction of Incorporation)

(Commission File Number)

(I.R.S. Employer Identification No.)

6166 Nancy Ridge Drive, San Diego, California 92121

(Address of Principal Executive Offices) (Zip Code)


(858) 453-7200

23-2908305

(Registrant s telephone number, including area code)

#### N/A

(Former Name or Former Address, if Changed Since Last Report)



#### Item 2.02. Results of Operations and Financial Condition.

On October 17, 2005, Arena Pharmaceuticals, Inc. issued a press release announcing its financial results for the third quarter and nine months ended September 30, 2005. The full text of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

#### Item 9.01. Financial Statements and Exhibits.

- (c) Exhibits.
- Press release issued October 17, 2005, announcing financial results for the third quarter and nine months ended September 30, 2005.

#### **SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: October 17, 2005 Arena Pharmaceuticals, Inc.,

a Delaware corporation

By: /s/ Steven W. Spector

Steven W. Spector

Senior Vice President, General Counsel and

Secretary

2

#### EXHIBIT INDEX

# Press release issued October 17, 2005, announcing financial results for the third quarter and nine months ended September 30, 2005.

23-2908305